![](https://news.europawire.eu/wp-content/uploads/2023/09/novartis-pavillon-scaled-e1733739094175-144x144.jpg)
(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). Scemblix achieved significantly higher major … Read the full press release